Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes
Yaping Chu, Scott Muller, Adriana Tavares, et al.
Brain (2019) Vol. 142, Iss. 11, pp. 3565-3579
Open Access | Times Cited: 95

Showing 1-25 of 95 citing articles:

Modeling Parkinson’s Disease With the Alpha-Synuclein Protein
Mónica Gómez-Benito, Noelia Granado, Patricia García‐Sanz, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 312
The pathogenesis of Parkinson's disease
Huw R. Morris, Maria Grazia Spillantini, Carolyn M. Sue, et al.
The Lancet (2024) Vol. 403, Iss. 10423, pp. 293-304
Open Access | Times Cited: 274
Initiation and propagation of α-synuclein aggregation in the nervous system
Baraa Hijaz, Laura A. Volpicelli‐Daley
Molecular Neurodegeneration (2020) Vol. 15, Iss. 1
Open Access | Times Cited: 201
Reverse engineering Lewy bodies: how far have we come and how far can we go?
Mohamed Bilal Fares, Somanath Jagannath, Hilal A. Lashuel
Nature reviews. Neuroscience (2021) Vol. 22, Iss. 2, pp. 111-131
Closed Access | Times Cited: 140
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
Luís M. A. Oliveira, Thomas Gasser, Robert H. Edwards, et al.
npj Parkinson s Disease (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 114
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
D. Volc, Werner Poewe, Alexandra Kutzelnigg, et al.
The Lancet Neurology (2020) Vol. 19, Iss. 7, pp. 591-600
Closed Access | Times Cited: 105
Exosomes in Parkinson disease
Jennifer R. Pinnell, Mei Cui, Kim Tieu
Journal of Neurochemistry (2020) Vol. 157, Iss. 3, pp. 413-428
Open Access | Times Cited: 100
Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies
Inês Caldeira Brás, Tiago F. Outeiro
Cells (2021) Vol. 10, Iss. 2, pp. 375-375
Open Access | Times Cited: 92
Determinants of seeding and spreading of α-synuclein pathology in the brain
Martin T. Henrich, Fanni F. Geibl, Lakshminarasimhan Harini, et al.
Science Advances (2020) Vol. 6, Iss. 46
Open Access | Times Cited: 81
Evidence of distinct α-synuclein strains underlying disease heterogeneity
Sara A. M. Holec, Amanda L. Woerman
Acta Neuropathologica (2020) Vol. 142, Iss. 1, pp. 73-86
Closed Access | Times Cited: 70
Initiation and progression of α-synuclein pathology in Parkinson’s disease
George K. Tofaris
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 4
Open Access | Times Cited: 66
Neurodegeneration and neuroinflammation are linked, but independent of alpha‐synuclein inclusions, in a seeding/spreading mouse model of Parkinson's disease
Pierre Garcia, Wiebke M. Wemheuer, Oihane Uriarte Huarte, et al.
Glia (2022) Vol. 70, Iss. 5, pp. 935-960
Open Access | Times Cited: 53
Monitoring α-synuclein aggregation
Juan Estaun-Panzano, Marie-Laure Arotçarena, Erwan Bézard
Neurobiology of Disease (2022) Vol. 176, pp. 105966-105966
Open Access | Times Cited: 48
Risk Factors for Phenoconversion in Rapid Eye Movement Sleep Behavior Disorder
Hui Zhang, Álex Iranzo, Birgit Högl, et al.
Annals of Neurology (2022) Vol. 91, Iss. 3, pp. 404-416
Closed Access | Times Cited: 45
Propagation of tau and α-synuclein in the brain: therapeutic potential of the glymphatic system
Douglas M. Lopes, Sophie K. Llewellyn, Ian F. Harrison
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 43
Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts
Margaux Teil, Marie-Laure Arotçarena, Emilie Faggiani, et al.
Biomolecules (2020) Vol. 10, Iss. 3, pp. 391-391
Open Access | Times Cited: 55
Copper and iron ions accelerate the prion-like propagation of α-synuclein: A vicious cycle in Parkinson's disease
Yang Li, Chen Yang, Shilin Wang, et al.
International Journal of Biological Macromolecules (2020) Vol. 163, pp. 562-573
Closed Access | Times Cited: 53
Intranasal administration of α-synuclein preformed fibrils triggers microglial iron deposition in the substantia nigra of Macaca fascicularis
Jianjun Guo, Feng Yue, Dong‐Yan Song, et al.
Cell Death and Disease (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 51
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study
Werner Poewe, D. Volc, Klaus Seppi, et al.
Journal of Parkinson s Disease (2021) Vol. 11, Iss. 3, pp. 1079-1089
Open Access | Times Cited: 47
Treadmill exercise reduces α-synuclein spreading via PPARα
Debashis Dutta, Ramesh Kumar Paidi, Sumita Raha, et al.
Cell Reports (2022) Vol. 40, Iss. 2, pp. 111058-111058
Open Access | Times Cited: 32
The role of NURR1 in metabolic abnormalities of Parkinson’s disease
Murad Al‐Nusaif, Yuting Yang, Song Li, et al.
Molecular Neurodegeneration (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 31
Dopaminergic modulation of primary motor cortex: From cellular and synaptic mechanisms underlying motor learning to cognitive symptoms in Parkinson’s disease
Jérémy Cousineau, Valentin Plateau, Jérôme Baufreton, et al.
Neurobiology of Disease (2022) Vol. 167, pp. 105674-105674
Open Access | Times Cited: 28
Unconventional secretion of α-synuclein mediated by palmitoylated DNAJC5 oligomers
Shenjie Wu, Nancy C. Hernandez Villegas, Daniel W. Sirkis, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 20
Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α‐Synuclein
Poul Henning Jensen, Michael G. Schlossmacher, Leonidas Stefanis
Movement Disorders (2023) Vol. 38, Iss. 3, pp. 378-384
Open Access | Times Cited: 18
Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates
Mathieu Bourdenx, Aurélien Nioche, Sandra Doveró, et al.
Science Advances (2020) Vol. 6, Iss. 20
Open Access | Times Cited: 49
Page 1 - Next Page

Scroll to top